Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 137

1.

Proven non-carriers in BRCA families have an earlier age of onset of breast cancer.

Vos JR, de Bock GH, Teixeira N, van der Kolk DM, Jansen L, Mourits MJ, Oosterwijk JC.

Eur J Cancer. 2013 Jun;49(9):2101-6. doi: 10.1016/j.ejca.2013.02.018. Epub 2013 Mar 13.

2.

Family history of breast and ovarian cancers and BRCA1 and BRCA2 mutations in a population-based series of early-onset breast cancer.

Loman N, Johannsson O, Kristoffersson U, Olsson H, Borg A.

J Natl Cancer Inst. 2001 Aug 15;93(16):1215-23.

PMID:
11504767
3.

Penetrance of breast cancer, ovarian cancer and contralateral breast cancer in BRCA1 and BRCA2 families: high cancer incidence at older age.

van der Kolk DM, de Bock GH, Leegte BK, Schaapveld M, Mourits MJ, de Vries J, van der Hout AH, Oosterwijk JC.

Breast Cancer Res Treat. 2010 Dec;124(3):643-51. doi: 10.1007/s10549-010-0805-3. Epub 2010 Mar 4.

PMID:
20204502
4.

Breast and ovarian cancer in relatives of cancer patients, with and without BRCA mutations.

Lee JS, John EM, McGuire V, Felberg A, Ostrow KL, DiCioccio RA, Li FP, Miron A, West DW, Whittemore AS.

Cancer Epidemiol Biomarkers Prev. 2006 Feb;15(2):359-63.

5.

Skewed X chromosome inactivation and breast and ovarian cancer status: evidence for X-linked modifiers of BRCA1.

Lose F, Duffy DL, Kay GF, Kedda MA, Spurdle AB; Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer.; Australian Ovarian Cancer Study Management Group..

J Natl Cancer Inst. 2008 Nov 5;100(21):1519-29. doi: 10.1093/jnci/djn345. Epub 2008 Oct 28.

PMID:
18957670
6.

Risk of ovarian cancer in BRCA1 and BRCA2 mutation-negative hereditary breast cancer families.

Kauff ND, Mitra N, Robson ME, Hurley KE, Chuai S, Goldfrank D, Wadsworth E, Lee J, Cigler T, Borgen PI, Norton L, Barakat RR, Offit K.

J Natl Cancer Inst. 2005 Sep 21;97(18):1382-4.

PMID:
16174860
7.
8.

Parity and the risk of breast and ovarian cancer in BRCA1 and BRCA2 mutation carriers.

Milne RL, Osorio A, Ramón y Cajal T, Baiget M, Lasa A, Diaz-Rubio E, de la Hoya M, Caldés T, Teulé A, Lázaro C, Blanco I, Balmaña J, Sánchez-Ollé G, Vega A, Blanco A, Chirivella I, Esteban Cardeñosa E, Durán M, Velasco E, Martínez de Dueñas E, Tejada MI, Miramar MD, Calvo MT, Guillén-Ponce C, Salazar R, San Román C, Urioste M, Benítez J.

Breast Cancer Res Treat. 2010 Jan;119(1):221-32. doi: 10.1007/s10549-009-0394-1. Epub 2009 Apr 16.

PMID:
19370414
9.

Cancer incidence in relatives of a population-based set of cases of early-onset breast cancer with a known BRCA1 and BRCA2 mutation status.

Loman N, Bladström A, Johannsson O, Borg A, Olsson H.

Breast Cancer Res. 2003;5(6):R175-86. Epub 2003 Aug 7.

10.

Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies.

Antoniou A, Pharoah PD, Narod S, Risch HA, Eyfjord JE, Hopper JL, Loman N, Olsson H, Johannsson O, Borg A, Pasini B, Radice P, Manoukian S, Eccles DM, Tang N, Olah E, Anton-Culver H, Warner E, Lubinski J, Gronwald J, Gorski B, Tulinius H, Thorlacius S, Eerola H, Nevanlinna H, Syrjäkoski K, Kallioniemi OP, Thompson D, Evans C, Peto J, Lalloo F, Evans DG, Easton DF.

Am J Hum Genet. 2003 May;72(5):1117-30. Epub 2003 Apr 3. Erratum in: Am J Hum Genet. 2003 Sep;73(3):709.

11.

BRCA1 and BRCA2 mutation predictions using the BOADICEA and BRCAPRO models and penetrance estimation in high-risk French-Canadian families.

Antoniou AC, Durocher F, Smith P, Simard J, Easton DF; INHERIT BRCAs program members..

Breast Cancer Res. 2006;8(1):R3. Epub 2005 Dec 12.

12.

Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers.

Rebbeck TR, Kauff ND, Domchek SM.

J Natl Cancer Inst. 2009 Jan 21;101(2):80-7. doi: 10.1093/jnci/djn442. Epub 2009 Jan 13.

13.

Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program.

Brose MS, Rebbeck TR, Calzone KA, Stopfer JE, Nathanson KL, Weber BL.

J Natl Cancer Inst. 2002 Sep 18;94(18):1365-72.

PMID:
12237282
14.

Phenocopy breast cancer rates in Israeli BRCA1 BRCA2 mutation carrier families: is the risk increased in non-carriers?

Bernholtz S, Laitman Y, Kaufman B, Shimon-Paluch S, Friedman E.

Breast Cancer Res Treat. 2012 Apr;132(2):669-73. doi: 10.1007/s10549-011-1886-3. Epub 2011 Nov 24.

PMID:
22113258
15.

Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada.

Risch HA, McLaughlin JR, Cole DE, Rosen B, Bradley L, Fan I, Tang J, Li S, Zhang S, Shaw PA, Narod SA.

J Natl Cancer Inst. 2006 Dec 6;98(23):1694-706.

PMID:
17148771
16.

Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers.

Narod SA, Dubé MP, Klijn J, Lubinski J, Lynch HT, Ghadirian P, Provencher D, Heimdal K, Moller P, Robson M, Offit K, Isaacs C, Weber B, Friedman E, Gershoni-Baruch R, Rennert G, Pasini B, Wagner T, Daly M, Garber JE, Neuhausen SL, Ainsworth P, Olsson H, Evans G, Osborne M, Couch F, Foulkes WD, Warner E, Kim-Sing C, Olopade O, Tung N, Saal HM, Weitzel J, Merajver S, Gauthier-Villars M, Jernstrom H, Sun P, Brunet JS.

J Natl Cancer Inst. 2002 Dec 4;94(23):1773-9.

PMID:
12464649
17.

Breast cancer risks in women with a family history of breast or ovarian cancer who have tested negative for a BRCA1 or BRCA2 mutation.

Metcalfe KA, Finch A, Poll A, Horsman D, Kim-Sing C, Scott J, Royer R, Sun P, Narod SA.

Br J Cancer. 2009 Jan 27;100(2):421-5. doi: 10.1038/sj.bjc.6604830. Epub 2008 Dec 16.

18.

Childhood cancer in families with and without BRCA1 or BRCA2 mutations ascertained at a high-risk breast cancer clinic.

Brooks GA, Stopfer JE, Erlichman J, Davidson R, Nathanson KL, Domchek SM.

Cancer Biol Ther. 2006 Sep;5(9):1098-102. Epub 2006 Sep 11.

PMID:
16931905
20.

The average cumulative risks of breast and ovarian cancer for carriers of mutations in BRCA1 and BRCA2 attending genetic counseling units in Spain.

Milne RL, Osorio A, Cajal TR, Vega A, Llort G, de la Hoya M, Díez O, Alonso MC, Lazaro C, Blanco I, Sánchez-de-Abajo A, Caldés T, Blanco A, Graña B, Durán M, Velasco E, Chirivella I, Cardeñosa EE, Tejada MI, Beristain E, Miramar MD, Calvo MT, Martínez E, Guillén C, Salazar R, San Román C, Antoniou AC, Urioste M, Benítez J.

Clin Cancer Res. 2008 May 1;14(9):2861-9. doi: 10.1158/1078-0432.CCR-07-4436.

Supplemental Content

Support Center